A Phase I/II Trial Of STI571 [imatinib] In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas.

Trial Profile

A Phase I/II Trial Of STI571 [imatinib] In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2013

At a glance

  • Drugs Imatinib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2010 Actual patient number (85) added as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Aug 2008 Actual study completion date added as 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top